The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the Tymlos label, and added the Drugs@FDA approval record. 12
What this version reported
A large randomized, placebo-controlled trial described in the label found fewer new spine fractures than placebo. The label states that abaloparatide caused osteosarcoma in rats and that it is unknown whether it does so in humans.↗
Reader guide in this version
Key takeaway
Abaloparatide is a lab-made analogue of PTHrP, a protein related to parathyroid hormone, and is the active ingredient in Tymlos.1,2 It is FDA-approved for postmenopausal women with osteoporosis at high risk of fracture, and to increase bone density in men with osteoporosis at high risk of fracture.1 In the label’s main trial of 1,645 postmenopausal women, new spine fractures over 18 months occurred in 0.6% of the abaloparatide group and 4.2% of the placebo group.1 The label states that abaloparatide caused a bone cancer called osteosarcoma in rats and that it is unknown whether it causes osteosarcoma in humans.1
At a glance
- What it is
- A PTHrP(1-34) analogue that the label says acts on the PTH1 receptor and stimulates new bone formation.1
- FDA status
- FDA-approved. Drugs@FDA lists Tymlos with an original approval date of April 28, 2017. The cited label has no boxed warning; its warnings include a risk of osteosarcoma seen in rats.1,2
- Human evidence
- A large randomized, placebo-controlled fracture trial in postmenopausal women and a smaller randomized trial in men, both described in the label.1
- Evidence strength
- Large randomized human trials
What is abaloparatide?
Abaloparatide is a lab-made peptide modelled on the first 34 amino acids of parathyroid hormone-related protein (PTHrP). The label describes it as a PTHrP(1-34) analogue.1
In the United States it is the active ingredient of Tymlos, according to Drugs@FDA.2
How does abaloparatide work?
The label states that abaloparatide activates the PTH1 receptor, which stimulates bone-building cells called osteoblasts and new bone formation.1
The label reports that in rats and monkeys it increased bone density and bone mineral content, which correlated with increased bone strength.1
What do human studies show?
The label describes an 18-month randomized, double-blind, placebo-controlled trial in 1,645 postmenopausal women with osteoporosis. New spine fractures occurred in 0.6% of the abaloparatide group and 4.2% of the placebo group, a relative risk reduction of 86%.1
Fractures outside the spine occurred in 2.7% of the abaloparatide group and 4.7% of the placebo group by the end of the treatment period, according to the label.1
In a 12-month randomized trial of 228 men with osteoporosis, the label reports increases in bone density. The label’s indication for men is to increase bone density, not to reduce fractures.1
The label states that the safety and effectiveness of abaloparatide have not been evaluated beyond 2 years of treatment.1
What the evidence base contains
- Large randomized human trial Study 003 (NCT01343004): an 18-month randomized, double-blind, placebo-controlled trial in 1,645 participants, postmenopausal women aged 49 to 86 with osteoporosis, with new spine fractures as the main outcome.1
- Controlled human trial Study 019 (NCT03512262): a 12-month randomized, double-blind, placebo-controlled trial in 228 men with osteoporosis that measured bone density.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Is abaloparatide FDA-approved?
Yes. Drugs@FDA lists Tymlos, application NDA208743, with an original approval date of April 28, 2017.2
The Tymlos label cited here (DailyMed SPL version 19, published August 17, 2026) states that it is indicated for postmenopausal women with osteoporosis at high risk for fracture, or who have failed or cannot tolerate other osteoporosis therapy, and to increase bone density in men with osteoporosis at high risk for fracture.1
The label has no boxed warning. It states that abaloparatide is contraindicated in people with a history of severe allergic reactions to it, which have included anaphylaxis and angioedema.1
Its warnings cover allergic reactions, a risk of osteosarcoma based on rat studies, a fall in blood pressure on standing, high blood calcium, and high urine calcium with kidney stones.1
What is still unknown?
Whether abaloparatide causes osteosarcoma in humans, which the label says is unknown.1
Its effects beyond 2 years of treatment, which the label says have not been evaluated.1
Whether it reduces fractures in men: the label’s trial in men measured bone density.1
Sources for this version
- 1TYMLOS (abaloparatide) injection, solution · SPL version 19 · published 2026-08-17 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 2Drugs@FDA application NDA208743 · original submission status AP · 2017-04-28 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026